Skip to content

Diagnostic study of gallium-68 labeled integrin receptor probe (68Ga-010) in patients with NSCLC

Diagnostic study of gallium-68 labeled integrin receptor probe (68Ga-010) in patients with NSCLC

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094498
Enrollment
Unknown
Registered
2024-12-24
Start date
2024-12-30
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

Experimental group:18F-FDG imaging agent, 68Ga-010 imaging agent

Sponsors

Henan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Non-Small Cell Lung Cancer Enrollment Criteria: each subject must meet all enrollment criteria to be eligible for the study: 1. the subject or his/her legal representative is able to sign the informed consent form; 2. commitment to comply with the study procedures and to cooperate with the implementation of the entire study; 3. adult patients (age 18 years or above) of either sex;

Exclusion criteria

Exclusion criteria: Subject exclusion criteria such as non-small cell lung cancer: subjects meeting any of the exclusion criteria were excluded: 1. allergies; 2. acute illness occurring prior to the study; 3. those who have undergone surgery within 6 months prior to the trial that, in the judgment of the investigator, will affect drug absorption, distribution, metabolism, or excretion; 4. those who have used any drugs (including prescription drugs, over-the-counter drugs, and herbal medicines) within 2 weeks prior to the trial; 5. pregnant and lactating women; 6. subjects with standard contraindications to PET/CT imaging; 7. significant claustrophobia; 8. subjects with poor glycemic control (fasting glucose > 11 mmol/L on the day of the experiment) due to diabetes mellitus or other medical conditions, or other reasons for not being able to undergo PET/CT; 9. subjects who are unable or unwilling to tolerate prolonged supine positioning during treatment.

Design outcomes

Primary

MeasureTime frame
SUVmax;

Countries

China

Contacts

Public ContactMeiyun Wang

Henan Provincial People's Hospital

mywang@zzu.edu.cn+86 371 8716 0589

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026